Dermatopharmacokinetics may not be appropriate for follicle-targeted topicals -- FDA.
This article was originally published in The Rose Sheet
Executive Summary
DERMATOPHARMACOKINETIC TESTS MAY NOT BE APPROPRIATE FOR FOLLICLE-TARGETED TOPICAL products in the evalua-tion of bioequivalence, FDA's Pharmaceutical Science Advisory Committee suggested in December. "We agree that if there are specific targets to the lower follicle, then the dermatopharmacokinetics may not be appropriate," the committee's acting chair, Cheryl Zimmerman, PhD, University of Minnesota, said.